pf-3450074 and HIV-Infections

pf-3450074 has been researched along with HIV-Infections* in 10 studies

Other Studies

10 other study(ies) available for pf-3450074 and HIV-Infections

ArticleYear
Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus.
    Nature microbiology, 2020, Volume: 5, Issue:9

    Retroviral infection involves the reverse transcription of the viral RNA genome into DNA, which is subsequently integrated into the host cell genome. Human immunodeficiency virus type 1 (HIV-1) and other lentiviruses mediate the infection of non-dividing cells through the ability of the capsid protein

    Topics: Active Transport, Cell Nucleus; Capsid; Capsid Proteins; CD4-Positive T-Lymphocytes; Cell Nucleus; Cytoplasm; HEK293 Cells; HeLa Cells; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Indoles; Macrophages; Nuclear Pore; Phenylalanine; Reverse Transcription; Virus Replication

2020
Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA.
    The EMBO journal, 2020, 10-15, Volume: 39, Issue:20

    Detection of viral DNA by cyclic GMP-AMP synthase (cGAS) is a first line of defence leading to the production of type I interferon (IFN). As HIV-1 replication is not a strong inducer of IFN, we hypothesised that an intact capsid physically cloaks viral DNA from cGAS. To test this, we generated defective viral particles by treatment with HIV-1 protease inhibitors or by genetic manipulation of gag. These viruses had defective Gag cleavage, reduced infectivity and diminished capacity to saturate TRIM5α. Importantly, unlike wild-type HIV-1, infection with cleavage defective HIV-1 triggered an IFN response in THP-1 cells that was dependent on viral DNA and cGAS. An IFN response was also observed in primary human macrophages infected with cleavage defective viruses. Infection in the presence of the capsid destabilising small molecule PF-74 also induced a cGAS-dependent IFN response. These data demonstrate a protective role for capsid and suggest that antiviral activity of capsid- and protease-targeting antivirals may benefit from enhanced innate and adaptive immunity in vivo.

    Topics: Adaptive Immunity; Antiviral Restriction Factors; Capsid; Cell Line; CRISPR-Cas Systems; DNA, Viral; Gene Editing; Gene Products, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Immunity, Innate; Indoles; Interferons; Macrophages; Membrane Proteins; Mutation; Nucleotidyltransferases; Phenylalanine; Signal Transduction; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Virus Replication

2020
PF74 Inhibits HIV-1 Integration by Altering the Composition of the Preintegration Complex.
    Journal of virology, 2019, 03-15, Volume: 93, Issue:6

    The HIV-1 capsid protein (CA) facilitates reverse transcription and nuclear entry of the virus. However, CA's role in post-nuclear entry steps remains speculative. We describe a direct link between CA and integration by employing the capsid inhibitor PF74 as a probe coupled with the biochemical analysis of HIV-1 preintegration complexes (PICs) isolated from acutely infected cells. At a low micromolar concentration, PF74 potently inhibited HIV-1 infection without affecting reverse transcription. Surprisingly, PF74 markedly reduced proviral integration owing to inhibition of nuclear entry and/or integration. However, a 2-fold reduction in nuclear entry by PF74 did not quantitatively correlate with the level of antiviral activity. Titration of PF74 against the integrase inhibitor raltegravir showed an additive antiviral effect that is dependent on a block at the post-nuclear entry step. PF74's inhibitory effect was not due to the formation of defective viral DNA ends or a delay in integration, suggesting that the compound inhibits PIC-associated integration activity. Unexpectedly, PICs recovered from cells infected in the presence of PF74 exhibited elevated integration activity. PF74's effect on PIC activity is CA specific since the compound did not increase the integration activity of PICs of a PF74-resistant HIV-1 CA mutant. Sucrose gradient-based fractionation studies revealed that PICs assembled in the presence of PF74 contained lower levels of CA, suggesting a negative association between CA and PIC-associated integration activity. Finally, the addition of a CA-specific antibody or PF74 inhibited PIC-associated integration activity. Collectively, our results demonstrate that PF74's targeting of PIC-associated CA results in impaired HIV-1 integration.

    Topics: Anti-HIV Agents; Capsid; Capsid Proteins; Cell Line; DNA, Viral; HEK293 Cells; HIV Infections; HIV Seropositivity; HIV-1; Humans; Indoles; Phenylalanine; Reverse Transcription; Virus Integration; Virus Replication

2019
A Novel Phenotype Links HIV-1 Capsid Stability to cGAS-Mediated DNA Sensing.
    Journal of virology, 2019, 08-15, Volume: 93, Issue:16

    Topics: Amino Acid Sequence; Anti-HIV Agents; Capsid; Capsid Proteins; Cell Line, Tumor; Disease Resistance; DNA, Viral; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Indoles; Mutation; Nucleotidyltransferases; Phenylalanine; Protein Stability

2019
Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    The HIV-1 capsid (CA) protein plays essential roles in both early and late stages of HIV-1 replication and is considered an important, clinically unexploited therapeutic target. As such, small drug-like molecules that inhibit this critical HIV-1 protein have become a priority for several groups. Therefore, in this study we explore small molecule targeting of the CA protein, and in particular a very attractive inter-protomer pocket. We report the design, parallel synthesis, and anti-HIV-1 activity evaluation of a series of novel phenylalanine derivatives as HIV-1 CA protein inhibitors synthesized via Cu(I)-catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) reaction. We demonstrate robust inhibitory activity over a range of potencies against the HIV-1 NL

    Topics: Anti-HIV Agents; Capsid; Click Chemistry; HIV Infections; HIV-1; Humans; Molecular Dynamics Simulation; Phenylalanine; Small Molecule Libraries

2018
Complementary Assays Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells.
    Journal of virology, 2015, Volume: 89, Issue:10

    During uncoating, the conical capsid of HIV disassembles by dissociation of the p24 capsid protein (CA). Uncoating is known to be required for HIV replication, but the mechanism is poorly defined. Here, we examined the timing and effect of two capsid binding drugs (PF74 and BI2) on infectivity and capsid integrity in HIV-1-infected cells. The virus remained susceptible to the action of PF74 and BI2 for hours after uncoating as defined in parallel drug addition and cyclosporine (CsA) washout assays to detect the kinetics of drug susceptibility and uncoating, respectively. Resistance mutations in CA decreased the potency of these compounds, demonstrating that CA is the target of drug action. However, neither drug altered capsid integrity in a fluorescence microscopy-based assay. These data suggest that PF74 and BI2 do not alter HIV-1 uncoating but rather affect a later step in viral replication. Because both drugs bind CA, we hypothesized that a residual amount of CA associates with the viral complex after the loss of the conical capsid to serve as a target for these drugs. Superresolution structured illumination microscopy (SIM) revealed that CA localized to viral complexes in the nuclei of infected cells. Using image quantification, we determined that viral complexes localized in the nucleus displayed a smaller amount of CA than complexes at the nuclear membrane, in the cytoplasm, or in controls. Collectively, these data suggest that a subset of CA remains associated with the viral complex after uncoating and that this residual CA is the target of PF74 and BI2.. The HIV-1 capsid is a target of interest for new antiviral therapies. This conical capsid is composed of monomers of the viral CA protein. During HIV-1 replication, the capsid must disassemble by a poorly defined process called uncoating. CA has also been implicated in later steps of replication, including nuclear import and integration. In this study, we used cell-based assays to examine the effect of two CA binding drugs (PF74 and BI2) on viral replication in infected cells. HIV-1 was susceptible to both drugs for hours after uncoating, suggesting that these drugs affect later steps of viral replication. High-resolution structured illumination microscopy (SIM) revealed that a subset of CA localized to viral complexes in the nuclei of cells. Collectively, these data suggest that a subset of CA remains associated with the viral complex after uncoating, which may facilitate later steps of viral replication and serve as a drug target.

    Topics: Anti-HIV Agents; Capsid; Cell Line; Cell Nucleus; HEK293 Cells; HeLa Cells; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indoles; Phenylalanine; Virus Replication; Virus Uncoating

2015
HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry.
    Journal of virology, 2015, Volume: 89, Issue:17

    During HIV-1 infection of cells, the viral capsid plays critical roles in reverse transcription and nuclear entry of the virus. The capsid-targeting small molecule PF74 inhibits HIV-1 at early stages of infection. HIV-1 resistance to PF74 is complex, requiring multiple amino acid substitutions in the viral CA protein. Here we report the identification and analysis of a novel PF74-resistant mutant encoding amino acid changes in both domains of CA, three of which are near the pocket where PF74 binds. Interestingly, the mutant virus retained partial PF74 binding, and its replication was stimulated by the compound. The mutant capsid structure was not significantly perturbed by binding of PF74; rather, the mutations inhibited capsid interactions with CPSF6 and Nup153 and altered HIV-1 dependence on these host factors and on TNPO3. Moreover, the replication of the mutant virus was markedly impaired in activated primary CD4(+) T cells and macrophages. Our results suggest that HIV-1 escapes a capsid-targeting small molecule inhibitor by altering the virus's dependence on host factors normally required for entry into the nucleus. They further imply that clinical resistance to inhibitors targeting the PF74 binding pocket is likely to be strongly limited by functional constraints on HIV-1 evolution.. The HIV-1 capsid plays critical roles in early steps of infection and is an attractive target for therapy. Here we show that selection for resistance to a capsid-targeting small molecule inhibitor can result in viral dependence on the compound. The mutant virus was debilitated in primary T cells and macrophages--cellular targets of infection in vivo. The mutations also altered the virus's dependence on cellular factors that are normally required for HIV-1 entry into the nucleus. This work provides new information regarding mechanisms of HIV-1 resistance that should be useful in efforts to develop clinically useful drugs targeting the HIV-1 capsid.

    Topics: Amino Acid Substitution; Anti-HIV Agents; beta Karyopherins; Binding Sites; Capsid; Capsid Proteins; CD4-Positive T-Lymphocytes; Cell Line; Drug Resistance, Viral; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Indoles; Macrophages; Molecular Chaperones; mRNA Cleavage and Polyadenylation Factors; Nuclear Pore Complex Proteins; Phenylalanine; Protein Binding; Protein Conformation; RNA Interference; RNA, Small Interfering; Virus Internalization; Virus Replication

2015
Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    The HIV-1 capsid is involved in all infectious steps from reverse transcription to integration site selection, and is the target of multiple host cell and pharmacologic ligands. However, structural studies have been limited to capsid monomers (CA), and the mechanistic basis for how these ligands influence infection is not well understood. Here we show that a multi-subunit interface formed exclusively within CA hexamers mediates binding to linear epitopes within cellular cofactors NUP153 and CPSF6, and is competed for by the antiretroviral compounds PF74 and BI-2. Each ligand is anchored via a shared phenylalanine-glycine (FG) motif to a pocket within the N-terminal domain of one monomer, and all but BI-2 also make essential interactions across the N-terminal domain: C-terminal domain (NTD:CTD) interface to a second monomer. Dissociation of hexamer into CA monomers prevents high affinity interaction with CPSF6 and PF74, and abolishes binding to NUP153. The second interface is conformationally dynamic, but binding of NUP153 or CPSF6 peptides is accommodated by only one conformation. NUP153 and CPSF6 have overlapping binding sites, but each makes unique CA interactions that, when mutated selectively, perturb cofactor dependency. These results reveal that multiple ligands share an overlapping interface in HIV-1 capsid that is lost upon viral disassembly.

    Topics: Anti-HIV Agents; Binding Sites; Capsid; Capsid Proteins; HIV Infections; HIV-1; Humans; Indoles; Ligands; Models, Molecular; Models, Structural; mRNA Cleavage and Polyadenylation Factors; Mutation; Nuclear Pore Complex Proteins; Phenylalanine; Polycyclic Compounds; Polymerization; Protein Binding; Protein Structure, Tertiary; Reverse Transcription; Virion

2014
Structural basis of HIV-1 capsid recognition by PF74 and CPSF6.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Dec-30, Volume: 111, Issue:52

    Upon infection of susceptible cells by HIV-1, the conical capsid formed by ∼250 hexamers and 12 pentamers of the CA protein is delivered to the cytoplasm. The capsid shields the RNA genome and proteins required for reverse transcription. In addition, the surface of the capsid mediates numerous host-virus interactions, which either promote infection or enable viral restriction by innate immune responses. In the intact capsid, there is an intermolecular interface between the N-terminal domain (NTD) of one subunit and the C-terminal domain (CTD) of the adjacent subunit within the same hexameric ring. The NTD-CTD interface is critical for capsid assembly, both as an architectural element of the CA hexamer and pentamer and as a mechanistic element for generating lattice curvature. Here we report biochemical experiments showing that PF-3450074 (PF74), a drug that inhibits HIV-1 infection, as well as host proteins cleavage and polyadenylation specific factor 6 (CPSF6) and nucleoporin 153 kDa (NUP153), bind to the CA hexamer with at least 10-fold higher affinities compared with nonassembled CA or isolated CA domains. The crystal structure of PF74 in complex with the CA hexamer reveals that PF74 binds in a preformed pocket encompassing the NTD-CTD interface, suggesting that the principal inhibitory target of PF74 is the assembled capsid. Likewise, CPSF6 binds in the same pocket. Given that the NTD-CTD interface is a specific molecular signature of assembled hexamers in the capsid, binding of NUP153 at this site suggests that key features of capsid architecture remain intact upon delivery of the preintegration complex to the nucleus.

    Topics: Capsid; Crystallography, X-Ray; HIV Infections; HIV-1; Indoles; mRNA Cleavage and Polyadenylation Factors; Nuclear Pore Complex Proteins; Phenylalanine; Protein Binding

2014
CPSF6 defines a conserved capsid interface that modulates HIV-1 replication.
    PLoS pathogens, 2012, Volume: 8, Issue:8

    The HIV-1 genome enters cells inside a shell comprised of capsid (CA) protein. Variation in CA sequence alters HIV-1 infectivity and escape from host restriction factors. However, apart from the Cyclophilin A-binding loop, CA has no known interfaces with which to interact with cellular cofactors. Here we describe a novel protein-protein interface in the N-terminal domain of HIV-1 CA, determined by X-ray crystallography, which mediates both viral restriction and host cofactor dependence. The interface is highly conserved across lentiviruses and is accessible in the context of a hexameric lattice. Mutation of the interface prevents binding to and restriction by CPSF6-358, a truncated cytosolic form of the RNA processing factor, cleavage and polyadenylation specific factor 6 (CPSF6). Furthermore, mutations that prevent CPSF6 binding also relieve dependence on nuclear entry cofactors TNPO3 and RanBP2. These results suggest that the HIV-1 capsid mediates direct host cofactor interactions to facilitate viral infection.

    Topics: Amino Acid Sequence; Antiviral Agents; beta Karyopherins; Capsid Proteins; Cell Line, Tumor; Conserved Sequence; Crystallography, X-Ray; HIV Infections; HIV-1; Humans; Indoles; Models, Molecular; Molecular Chaperones; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Nuclear Pore Complex Proteins; Phenylalanine; Protein Binding; Sequence Alignment; Virus Internalization; Virus Replication

2012